MX2012011379A - Inhibidores no nucleosidicos de la transcriptasa inversa. - Google Patents

Inhibidores no nucleosidicos de la transcriptasa inversa.

Info

Publication number: MX2012011379A
Authority: MX; Mexico
Prior art keywords: alkyl; independently; haloalkyl; compound; pharmaceutically acceptable
Prior art date: 2010-03-30

Application number

MX2012011379A

Other languages

English (en)

Spanish (es)

Inventor

Bernard Cote

Danny Gauvreau

Jason Burch

Natalie Nguyen

Chun Sing Li

Miguel St-Onge

Original Assignee

Merck Canada Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-03-30

Filing date

2011-03-28

Publication date

2012-11-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44710363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012011379(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-03-28 Application filed by Merck Canada Inc filed Critical Merck Canada Inc

2012-11-30 Publication of MX2012011379A publication Critical patent/MX2012011379A/es

Links

229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 title description 2
239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 236
150000003839 salts Chemical class 0.000 claims abstract description 105
238000011282 treatment Methods 0.000 claims abstract description 49
238000011321 prophylaxis Methods 0.000 claims abstract description 40
208000030507 AIDS Diseases 0.000 claims abstract description 37
108010078851 HIV Reverse Transcriptase Proteins 0.000 claims abstract description 28
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
239000003443 antiviral agent Substances 0.000 claims abstract description 13
125000000217 alkyl group Chemical group 0.000 claims description 123
125000001424 substituent group Chemical group 0.000 claims description 84
229910052799 carbon Inorganic materials 0.000 claims description 67
-1 O-C Chemical group 0.000 claims description 56
150000002367 halogens Chemical class 0.000 claims description 50
229910052736 halogen Inorganic materials 0.000 claims description 45
239000003112 inhibitor Substances 0.000 claims description 42
125000000753 cycloalkyl group Chemical group 0.000 claims description 39
229910052757 nitrogen Inorganic materials 0.000 claims description 38
125000001188 haloalkyl group Chemical group 0.000 claims description 36
125000005842 heteroatom Chemical group 0.000 claims description 32
208000031886 HIV Infections Diseases 0.000 claims description 31
229910052739 hydrogen Inorganic materials 0.000 claims description 31
208000037357 HIV infectious disease Diseases 0.000 claims description 30
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 30
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 28
125000003118 aryl group Chemical group 0.000 claims description 24
229910052717 sulfur Inorganic materials 0.000 claims description 23
125000001072 heteroaryl group Chemical group 0.000 claims description 20
229920006395 saturated elastomer Polymers 0.000 claims description 18
239000002777 nucleoside Substances 0.000 claims description 17
150000003833 nucleoside derivatives Chemical class 0.000 claims description 17
125000003709 fluoroalkyl group Chemical group 0.000 claims description 15
125000003342 alkenyl group Chemical group 0.000 claims description 14
239000003814 drug Substances 0.000 claims description 14
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
229910052760 oxygen Inorganic materials 0.000 claims description 12
125000000623 heterocyclic group Chemical group 0.000 claims description 11
125000001624 naphthyl group Chemical group 0.000 claims description 10
125000004432 carbon atom Chemical group C* 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
125000000392 cycloalkenyl group Chemical group 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 6
125000000304 alkynyl group Chemical group 0.000 claims description 5
239000004030 hiv protease inhibitor Substances 0.000 claims description 5
CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 5
229940099797 HIV integrase inhibitor Drugs 0.000 claims description 4
DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 claims description 4
101100273648 Mus musculus Ccna2 gene Proteins 0.000 claims description 4
230000004927 fusion Effects 0.000 claims description 4
239000003084 hiv integrase inhibitor Substances 0.000 claims description 4
239000002850 integrase inhibitor Substances 0.000 claims description 4
229940124524 integrase inhibitor Drugs 0.000 claims description 4
102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 3
108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 3
125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 3
125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims description 3
239000002835 hiv fusion inhibitor Substances 0.000 claims description 3
125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 2
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical group C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
230000005764 inhibitory process Effects 0.000 abstract description 16
239000004615 ingredient Substances 0.000 abstract description 8
239000002955 immunomodulating agent Substances 0.000 abstract description 5
229940121354 immunomodulator Drugs 0.000 abstract description 4
208000015181 infectious disease Diseases 0.000 abstract description 4
239000003419 rna directed dna polymerase inhibitor Substances 0.000 abstract description 4
229940042443 other antivirals in atc Drugs 0.000 abstract description 2
229960005486 vaccine Drugs 0.000 abstract description 2
239000003242 anti bacterial agent Substances 0.000 abstract 1
229940088710 antibiotic agent Drugs 0.000 abstract 1
150000002390 heteroarenes Chemical class 0.000 abstract 1
239000000203 mixture Substances 0.000 description 69
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 62
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
241000725303 Human immunodeficiency virus Species 0.000 description 51
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 47
238000000034 method Methods 0.000 description 30
239000000460 chlorine Substances 0.000 description 29
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 28
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 28
229940002612 prodrug Drugs 0.000 description 26
239000000651 prodrug Substances 0.000 description 26
239000007787 solid Substances 0.000 description 26
235000019439 ethyl acetate Nutrition 0.000 description 25
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 24
229910001868 water Inorganic materials 0.000 description 24
102100034343 Integrase Human genes 0.000 description 23
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
238000006243 chemical reaction Methods 0.000 description 21
239000000284 extract Substances 0.000 description 21
239000000243 solution Substances 0.000 description 20
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 20
238000000746 purification Methods 0.000 description 17
239000000047 product Substances 0.000 description 15
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
239000012267 brine Substances 0.000 description 14
239000000725 suspension Substances 0.000 description 14
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
239000002259 anti human immunodeficiency virus agent Substances 0.000 description 12
229940124411 anti-hiv antiviral agent Drugs 0.000 description 12
238000003556 assay Methods 0.000 description 12
229910052794 bromium Inorganic materials 0.000 description 12
229910052801 chlorine Inorganic materials 0.000 description 12
229910052731 fluorine Inorganic materials 0.000 description 12
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 10
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
108020004414 DNA Proteins 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
230000000840 anti-viral effect Effects 0.000 description 9
125000004122 cyclic group Chemical group 0.000 description 9
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
229910000027 potassium carbonate Inorganic materials 0.000 description 9
230000010076 replication Effects 0.000 description 9
JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 8
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 7
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 7
239000002253 acid Substances 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
230000004048 modification Effects 0.000 description 7
238000012986 modification Methods 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
238000001816 cooling Methods 0.000 description 6
150000004806 hydroxypyridines Chemical class 0.000 description 6
OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 6
125000003601 C2-C6 alkynyl group Chemical group 0.000 description 5
239000007832 Na2SO4 Substances 0.000 description 5
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
239000000872 buffer Substances 0.000 description 5
235000017557 sodium bicarbonate Nutrition 0.000 description 5
229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
229910052938 sodium sulfate Inorganic materials 0.000 description 5
235000011152 sodium sulphate Nutrition 0.000 description 5
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 4
BNRLRFLCIIEKJB-UHFFFAOYSA-N 3-(3-bromo-5-chlorophenoxy)-2-chloro-4-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=NC(Cl)=C1OC1=CC(Cl)=CC(Br)=C1 BNRLRFLCIIEKJB-UHFFFAOYSA-N 0.000 description 4
IIIPGVXKHUPPJQ-UHFFFAOYSA-N 3-(difluoromethyl)benzonitrile Chemical compound FC(F)C1=CC=CC(C#N)=C1 IIIPGVXKHUPPJQ-UHFFFAOYSA-N 0.000 description 4
KLFRYOYHJGWKAU-UHFFFAOYSA-N 3-[(4-bromo-2-oxo-1h-pyridin-3-yl)oxy]-5-chlorobenzonitrile Chemical compound OC1=NC=CC(Br)=C1OC1=CC(Cl)=CC(C#N)=C1 KLFRYOYHJGWKAU-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 4
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
229960005475 antiinfective agent Drugs 0.000 description 4
125000004429 atom Chemical group 0.000 description 4
239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
229940079593 drug Drugs 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
125000004433 nitrogen atom Chemical group N* 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
235000015320 potassium carbonate Nutrition 0.000 description 4
UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 4
238000003756 stirring Methods 0.000 description 4
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 3
XCNYQRAIAMBUNC-UHFFFAOYSA-N 2-chloro-3-(3-chloro-5-iodophenoxy)-4-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=NC(Cl)=C1OC1=CC(Cl)=CC(I)=C1 XCNYQRAIAMBUNC-UHFFFAOYSA-N 0.000 description 3
YKQVABFVOGPIKX-UHFFFAOYSA-N 2-chloro-3-fluoro-4-(trifluoromethyl)pyridine Chemical compound FC1=C(Cl)N=CC=C1C(F)(F)F YKQVABFVOGPIKX-UHFFFAOYSA-N 0.000 description 3
CDHYRAXSPMVANS-UHFFFAOYSA-N 3-(3-bromo-5-chlorophenoxy)-2,4-dichloropyridine Chemical compound ClC1=CC(Br)=CC(OC=2C(=NC=CC=2Cl)Cl)=C1 CDHYRAXSPMVANS-UHFFFAOYSA-N 0.000 description 3
MYNCKACPCAUSGK-UHFFFAOYSA-N 3-(3-bromo-5-chlorophenoxy)-4-(trifluoromethyl)-1h-pyridin-2-one Chemical compound C1=CNC(=O)C(OC=2C=C(Br)C=C(Cl)C=2)=C1C(F)(F)F MYNCKACPCAUSGK-UHFFFAOYSA-N 0.000 description 3
YNLOHEACLCNYPF-UHFFFAOYSA-N 3-(3-bromo-5-chlorophenoxy)-4-chloro-1h-pyridin-2-one Chemical compound OC1=NC=CC(Cl)=C1OC1=CC(Cl)=CC(Br)=C1 YNLOHEACLCNYPF-UHFFFAOYSA-N 0.000 description 3
FFJXSRWDORQRPQ-UHFFFAOYSA-N 3-(chloromethyl)-4-methyl-1h-1,2,4-triazol-5-one Chemical compound CN1C(CCl)=NNC1=O FFJXSRWDORQRPQ-UHFFFAOYSA-N 0.000 description 3
GRJFEPKRTUHYCB-UHFFFAOYSA-N 3-(difluoromethyl)-5-hydroxybenzonitrile Chemical compound OC1=CC(C#N)=CC(C(F)F)=C1 GRJFEPKRTUHYCB-UHFFFAOYSA-N 0.000 description 3
JVQISFAXAJZVDE-UHFFFAOYSA-N 3-(hydroxymethyl)-4-methyl-1h-1,2,4-triazol-5-one Chemical compound CN1C(CO)=NNC1=O JVQISFAXAJZVDE-UHFFFAOYSA-N 0.000 description 3
QBNIBNUEBBJVFN-UHFFFAOYSA-N 3-chloro-5-iodophenol Chemical compound OC1=CC(Cl)=CC(I)=C1 QBNIBNUEBBJVFN-UHFFFAOYSA-N 0.000 description 3
OOHDBOIRPXCEEN-UHFFFAOYSA-N 4-bromo-3-(3-chloro-5-iodophenoxy)-1h-pyridin-2-one Chemical compound OC1=NC=CC(Br)=C1OC1=CC(Cl)=CC(I)=C1 OOHDBOIRPXCEEN-UHFFFAOYSA-N 0.000 description 3
ZLRBJVJEQXBAAI-UHFFFAOYSA-N 5-(chloromethyl)-1,2-dihydro-1,2,4-triazol-3-one Chemical compound ClCC1=NC(=O)NN1 ZLRBJVJEQXBAAI-UHFFFAOYSA-N 0.000 description 3
206010001513 AIDS related complex Diseases 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 3
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
108020000999 Viral RNA Proteins 0.000 description 3
239000004599 antimicrobial Substances 0.000 description 3
239000012223 aqueous fraction Substances 0.000 description 3
230000037396 body weight Effects 0.000 description 3
WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 3
CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
239000011737 fluorine Substances 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 description 3
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
230000000155 isotopic effect Effects 0.000 description 3
230000002265 prevention Effects 0.000 description 3
239000011734 sodium Substances 0.000 description 3
125000004434 sulfur atom Chemical group 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
238000001665 trituration Methods 0.000 description 3
125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 2
125000006002 1,1-difluoroethyl group Chemical group 0.000 description 2
JMLWXCJXOYDXRN-UHFFFAOYSA-N 1-chloro-3-iodobenzene Chemical compound ClC1=CC=CC(I)=C1 JMLWXCJXOYDXRN-UHFFFAOYSA-N 0.000 description 2
AJNBGACVRJPPLU-UHFFFAOYSA-N 1-chloro-4h-triazol-5-one Chemical compound ClN1N=NCC1=O AJNBGACVRJPPLU-UHFFFAOYSA-N 0.000 description 2
CHZCERSEMVWNHL-UHFFFAOYSA-N 2-hydroxybenzonitrile Chemical compound OC1=CC=CC=C1C#N CHZCERSEMVWNHL-UHFFFAOYSA-N 0.000 description 2
GMGWXLPFRHYWAS-UHFFFAOYSA-N 3-bromo-5-chlorophenol Chemical compound OC1=CC(Cl)=CC(Br)=C1 GMGWXLPFRHYWAS-UHFFFAOYSA-N 0.000 description 2
LCIMTQHLKRQXAS-UHFFFAOYSA-N 4-methyl-1h-1,2,4-triazol-5-one Chemical compound CN1C=NNC1=O LCIMTQHLKRQXAS-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
239000010749 BS 2869 Class C1 Substances 0.000 description 2
239000010750 BS 2869 Class C2 Substances 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
206010034133 Pathogen resistance Diseases 0.000 description 2
YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 2
241000720974 Protium Species 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
108010083644 Ribonucleases Proteins 0.000 description 2
102000006382 Ribonucleases Human genes 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
238000006619 Stille reaction Methods 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
125000002947 alkylene group Chemical group 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
238000005576 amination reaction Methods 0.000 description 2
229940121357 antivirals Drugs 0.000 description 2
125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
125000003354 benzotriazolyl group Chemical class N1N=NC2=C1C=CC=C2* 0.000 description 2
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
125000002619 bicyclic group Chemical group 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
238000001311 chemical methods and process Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
239000012043 crude product Substances 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
229910052805 deuterium Inorganic materials 0.000 description 2
238000001035 drying Methods 0.000 description 2
230000009088 enzymatic function Effects 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
125000002883 imidazolyl group Chemical group 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000011630 iodine Substances 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
125000001786 isothiazolyl group Chemical group 0.000 description 2
239000010410 layer Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
125000002950 monocyclic group Chemical group 0.000 description 2
230000035772 mutation Effects 0.000 description 2
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
125000001715 oxadiazolyl group Chemical group 0.000 description 2
125000002971 oxazolyl group Chemical group 0.000 description 2
125000004430 oxygen atom Chemical group O* 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
229920000728 polyester Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
125000003373 pyrazinyl group Chemical group 0.000 description 2
125000003226 pyrazolyl group Chemical group 0.000 description 2
125000004076 pyridyl group Chemical group 0.000 description 2
125000000714 pyrimidinyl group Chemical group 0.000 description 2
125000000168 pyrrolyl group Chemical group 0.000 description 2
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
238000011160 research Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
239000003826 tablet Substances 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
238000012360 testing method Methods 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
125000001113 thiadiazolyl group Chemical group 0.000 description 2
125000000335 thiazolyl group Chemical group 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
229910052723 transition metal Inorganic materials 0.000 description 2
150000003624 transition metals Chemical class 0.000 description 2
BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
125000000391 vinyl group Chemical class [H]C([*])=C([H])[H] 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 description 1
YSIBYEBNVMDAPN-CMDGGOBGSA-N (e)-4-oxo-4-(3-triethoxysilylpropylamino)but-2-enoic acid Chemical compound CCO[Si](OCC)(OCC)CCCNC(=O)\C=C\C(O)=O YSIBYEBNVMDAPN-CMDGGOBGSA-N 0.000 description 1
125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
NUBQKPWHXMGDLP-UHFFFAOYSA-N 1-[4-benzyl-2-hydroxy-5-[(2-hydroxy-2,3-dihydro-1h-inden-1-yl)amino]-5-oxopentyl]-n-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide;sulfuric acid Chemical compound OS(O)(=O)=O.C1CN(CC(O)CC(CC=2C=CC=CC=2)C(=O)NC2C3=CC=CC=C3CC2O)C(C(=O)NC(C)(C)C)CN1CC1=CC=CN=C1 NUBQKPWHXMGDLP-UHFFFAOYSA-N 0.000 description 1
LHYKTQVFLKHQSR-UHFFFAOYSA-N 1-amino-3-methylurea Chemical compound CNC(=O)NN LHYKTQVFLKHQSR-UHFFFAOYSA-N 0.000 description 1
125000004973 1-butenyl group Chemical class C(=CCC)* 0.000 description 1
125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 1
IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
125000004974 2-butenyl group Chemical class C(C=CC)* 0.000 description 1
125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
IOYIMFJNYAIBRT-UHFFFAOYSA-N 2-chloro-3-(3-chloro-5-iodophenoxy)-4-nitro-1-oxidopyridin-1-ium Chemical compound [O-][N+](=O)C1=CC=[N+]([O-])C(Cl)=C1OC1=CC(Cl)=CC(I)=C1 IOYIMFJNYAIBRT-UHFFFAOYSA-N 0.000 description 1
FNRMMDCDHWCQTH-UHFFFAOYSA-N 2-chloropyridine;3-chloropyridine;4-chloropyridine Chemical compound ClC1=CC=NC=C1.ClC1=CC=CN=C1.ClC1=CC=CC=N1 FNRMMDCDHWCQTH-UHFFFAOYSA-N 0.000 description 1
YXVABPSUOVOEJJ-UHFFFAOYSA-N 2-methyl-6-[(6-phenoxypyridin-2-yl)methyl]pyridine Chemical compound CC1=CC=CC(CC=2N=C(OC=3C=CC=CC=3)C=CC=2)=N1 YXVABPSUOVOEJJ-UHFFFAOYSA-N 0.000 description 1
QISAUDWTBBNJIR-UHFFFAOYSA-N 2-phenylmethoxyacetyl chloride Chemical compound ClC(=O)COCC1=CC=CC=C1 QISAUDWTBBNJIR-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical class [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
FMHPFOIODIOBIC-UHFFFAOYSA-N 3-(3-bromo-5-chlorophenoxy)-2-chloro-4-nitro-1-oxidopyridin-1-ium Chemical compound [O-][N+](=O)C1=CC=[N+]([O-])C(Cl)=C1OC1=CC(Cl)=CC(Br)=C1 FMHPFOIODIOBIC-UHFFFAOYSA-N 0.000 description 1
QGISZFWUDRKBSX-UHFFFAOYSA-N 3-(3-chloro-5-iodophenoxy)-4-(trifluoromethyl)-1h-pyridin-2-one Chemical compound OC1=NC=CC(C(F)(F)F)=C1OC1=CC(Cl)=CC(I)=C1 QGISZFWUDRKBSX-UHFFFAOYSA-N 0.000 description 1
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
GXWCVUKXEQPBJL-UHFFFAOYSA-N 3-[(4-acetyl-2-oxo-1h-pyridin-3-yl)oxy]-5-chlorobenzonitrile Chemical compound CC(=O)C1=CC=NC(O)=C1OC1=CC(Cl)=CC(C#N)=C1 GXWCVUKXEQPBJL-UHFFFAOYSA-N 0.000 description 1
VFOCWLDAUKCBOJ-UHFFFAOYSA-N 3-[(5-bromo-4-chloro-2-oxo-1h-pyridin-3-yl)oxy]-5-chlorobenzonitrile Chemical compound OC1=NC=C(Br)C(Cl)=C1OC1=CC(Cl)=CC(C#N)=C1 VFOCWLDAUKCBOJ-UHFFFAOYSA-N 0.000 description 1
125000004975 3-butenyl group Chemical class C(CC=C)* 0.000 description 1
125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
YDLPCCWJPWQVTG-UHFFFAOYSA-N 3-chloro-5-[(4-chloro-2-oxo-1h-pyridin-3-yl)oxy]benzonitrile Chemical compound OC1=NC=CC(Cl)=C1OC1=CC(Cl)=CC(C#N)=C1 YDLPCCWJPWQVTG-UHFFFAOYSA-N 0.000 description 1
HWTORHRJFMRBLG-UHFFFAOYSA-N 3-chloro-5-[[2-oxo-4-(trifluoromethyl)-1h-pyridin-3-yl]oxy]benzonitrile Chemical compound OC1=NC=CC(C(F)(F)F)=C1OC1=CC(Cl)=CC(C#N)=C1 HWTORHRJFMRBLG-UHFFFAOYSA-N 0.000 description 1
UXNXDFXLRMVDCA-UHFFFAOYSA-N 3-fluoro-1-[(4-methyl-5-oxo-1h-1,2,4-triazol-3-yl)methyl]-4-(trifluoromethyl)pyridin-2-one Chemical compound N1C(=O)N(C)C(CN2C(C(F)=C(C=C2)C(F)(F)F)=O)=N1 UXNXDFXLRMVDCA-UHFFFAOYSA-N 0.000 description 1
DQZPMFOHJSLGIA-UHFFFAOYSA-N 3-fluoro-1-oxido-4-(trifluoromethyl)pyridin-1-ium Chemical compound [O-][N+]1=CC=C(C(F)(F)F)C(F)=C1 DQZPMFOHJSLGIA-UHFFFAOYSA-N 0.000 description 1
CUVQCPUTFJFSFU-UHFFFAOYSA-N 3-fluoro-4-(trifluoromethyl)-1h-pyridin-2-one Chemical compound OC1=NC=CC(C(F)(F)F)=C1F CUVQCPUTFJFSFU-UHFFFAOYSA-N 0.000 description 1
AXHLDFPTUFGBRL-UHFFFAOYSA-N 3-fluoro-4-(trifluoromethyl)pyridine Chemical compound FC1=CN=CC=C1C(F)(F)F AXHLDFPTUFGBRL-UHFFFAOYSA-N 0.000 description 1
HGZJJKZPPMFIBU-UHFFFAOYSA-N 3-formylbenzonitrile Chemical compound O=CC1=CC=CC(C#N)=C1 HGZJJKZPPMFIBU-UHFFFAOYSA-N 0.000 description 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
VERWQPYQDXWOGT-LVJNJWHOSA-N 4-amino-5-fluoro-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;[[(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VERWQPYQDXWOGT-LVJNJWHOSA-N 0.000 description 1
XQKOUEBIJOSTKI-UHFFFAOYSA-N 4-methyl-3-(phenylmethoxymethyl)-1h-1,2,4-triazol-5-one Chemical compound N1C(=O)N(C)C(COCC=2C=CC=CC=2)=N1 XQKOUEBIJOSTKI-UHFFFAOYSA-N 0.000 description 1
GZVJKNAPQDHVHH-UHFFFAOYSA-N 5-benzyl-1h-pyridazin-6-one Chemical class O=C1NN=CC=C1CC1=CC=CC=C1 GZVJKNAPQDHVHH-UHFFFAOYSA-N 0.000 description 1
MNHHPSZWDLULCV-UHFFFAOYSA-N 5-chloro-1-iodocyclohexa-2,4-dien-1-ol Chemical compound OC1(I)CC(Cl)=CC=C1 MNHHPSZWDLULCV-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
208000032484 Accidental exposure to product Diseases 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
108010019625 Atazanavir Sulfate Proteins 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
208000003014 Bites and Stings Diseases 0.000 description 1
JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
108020001019 DNA Primers Proteins 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
108010010369 HIV Protease Proteins 0.000 description 1
108010081348 HRT1 protein Hairy Proteins 0.000 description 1
102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 1
108700020129 Human immunodeficiency virus 1 p31 integrase Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
206010069803 Injury associated with device Diseases 0.000 description 1
108010061833 Integrases Proteins 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
239000012425 OXONE® Substances 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
229910020667 PBr3 Inorganic materials 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
101100042881 Sambucus nigra SNA-I gene Proteins 0.000 description 1
IRHXGOXEBNJUSN-YOXDLBRISA-N Saquinavir mesylate Chemical compound CS(O)(=O)=O.C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 IRHXGOXEBNJUSN-YOXDLBRISA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
101100073357 Streptomyces halstedii sch2 gene Proteins 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
LBZXELUWKIEZEQ-MYINAIGISA-N [[(2r,3s,5s)-5-bromo-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@]1(Br)N1C(=O)NC(=O)C=C1 LBZXELUWKIEZEQ-MYINAIGISA-N 0.000 description 1
MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
229960004748 abacavir Drugs 0.000 description 1
WMHSRBZIJNQHKT-FFKFEZPRSA-N abacavir sulfate Chemical compound OS(O)(=O)=O.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 WMHSRBZIJNQHKT-FFKFEZPRSA-N 0.000 description 1
229960000531 abacavir sulfate Drugs 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
FXXACINHVKSMDR-UHFFFAOYSA-N acetyl bromide Chemical compound CC(Br)=O FXXACINHVKSMDR-UHFFFAOYSA-N 0.000 description 1
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
239000012346 acetyl chloride Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
238000000137 annealing Methods 0.000 description 1
125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
230000002924 anti-infective effect Effects 0.000 description 1
229940124425 anti-infective immunomodulator Drugs 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
150000001491 aromatic compounds Chemical class 0.000 description 1
238000007080 aromatic substitution reaction Methods 0.000 description 1
125000004104 aryloxy group Chemical group 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
229960003796 atazanavir sulfate Drugs 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
125000003725 azepanyl group Chemical group 0.000 description 1
125000002393 azetidinyl group Chemical group 0.000 description 1
150000003851 azoles Chemical class 0.000 description 1
239000002585 base Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
150000001556 benzimidazoles Chemical class 0.000 description 1
125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
229910000085 borane Inorganic materials 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
230000031709 bromination Effects 0.000 description 1
238000005893 bromination reaction Methods 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
HGXJOXHYPGNVNK-UHFFFAOYSA-N butane;ethenoxyethane;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C(=C)OCC HGXJOXHYPGNVNK-UHFFFAOYSA-N 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
VZSXFJPZOCRDPW-UHFFFAOYSA-N carbanide;trioxorhenium Chemical compound [CH3-].O=[Re](=O)=O VZSXFJPZOCRDPW-UHFFFAOYSA-N 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
229960005319 delavirdine Drugs 0.000 description 1
MEPNHSOMXMALDZ-UHFFFAOYSA-N delavirdine mesylate Chemical compound CS(O)(=O)=O.CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 MEPNHSOMXMALDZ-UHFFFAOYSA-N 0.000 description 1
229960000475 delavirdine mesylate Drugs 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
125000005959 diazepanyl group Chemical group 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
125000000532 dioxanyl group Chemical group 0.000 description 1
WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
238000009510 drug design Methods 0.000 description 1
230000036267 drug metabolism Effects 0.000 description 1
XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
229960003804 efavirenz Drugs 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000012458 free base Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
229940125777 fusion inhibitor Drugs 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
230000036541 health Effects 0.000 description 1
229940037467 helicobacter pylori Drugs 0.000 description 1
125000006038 hexenyl group Chemical class 0.000 description 1
125000005980 hexynyl group Chemical class 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
150000002460 imidazoles Chemical class 0.000 description 1
125000002632 imidazolidinyl group Chemical group 0.000 description 1
150000002466 imines Chemical class 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
229960004243 indinavir sulfate Drugs 0.000 description 1
125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000010354 integration Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000003874 inverse correlation nuclear magnetic resonance spectroscopy Methods 0.000 description 1
HVTICUPFWKNHNG-BJUDXGSMSA-N iodoethane Chemical group [11CH3]CI HVTICUPFWKNHNG-BJUDXGSMSA-N 0.000 description 1
125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
125000003965 isoxazolidinyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
238000006241 metabolic reaction Methods 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
KYPIASPTMDEDQB-UHFFFAOYSA-N n,2-diphenylacetamide Chemical class C=1C=CC=CC=1NC(=O)CC1=CC=CC=C1 KYPIASPTMDEDQB-UHFFFAOYSA-N 0.000 description 1
125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
229960005230 nelfinavir mesylate Drugs 0.000 description 1
NQHXCOAXSHGTIA-SKXNDZRYSA-N nelfinavir mesylate Chemical compound CS(O)(=O)=O.CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 NQHXCOAXSHGTIA-SKXNDZRYSA-N 0.000 description 1
229960000689 nevirapine Drugs 0.000 description 1
125000006574 non-aromatic ring group Chemical group 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
239000012038 nucleophile Substances 0.000 description 1
238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
239000013110 organic ligand Substances 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
ZVTQYRVARPYRRE-UHFFFAOYSA-N oxadiazol-4-one Chemical class O=C1CON=N1 ZVTQYRVARPYRRE-UHFFFAOYSA-N 0.000 description 1
125000000160 oxazolidinyl group Chemical group 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
125000002255 pentenyl group Chemical class C(=CCCC)* 0.000 description 1
125000005981 pentynyl group Chemical class 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
239000006187 pill Substances 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
108700004029 pol Genes Proteins 0.000 description 1
101150088264 pol gene Proteins 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
125000003072 pyrazolidinyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
150000003242 quaternary ammonium salts Chemical class 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
238000010992 reflux Methods 0.000 description 1
125000006413 ring segment Chemical group 0.000 description 1
229910052707 ruthenium Inorganic materials 0.000 description 1
229960003542 saquinavir mesylate Drugs 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000779 smoke Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
238000003797 solvolysis reaction Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
125000000565 sulfonamide group Chemical group 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000003419 tautomerization reaction Methods 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
125000006407 thiazinanyl group Chemical group 0.000 description 1
125000001984 thiazolidinyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
125000004568 thiomorpholinyl group Chemical group 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000017105 transposition Effects 0.000 description 1
125000004306 triazinyl group Chemical group 0.000 description 1
FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000009423 ventilation Methods 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000011701 zinc Substances 0.000 description 1
GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
General Chemical & Material Sciences (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

MX2012011379A 2010-03-30 2011-03-28 Inhibidores no nucleosidicos de la transcriptasa inversa. MX2012011379A (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US31882410P	2010-03-30	2010-03-30
US32157310P	2010-04-07	2010-04-07
CA2011100320		2011-03-28

Publications (1)

Publication Number	Publication Date
MX2012011379A true MX2012011379A (es)	2012-11-30

Family

ID=44710363

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MX2012011379A MX2012011379A (es)	2010-03-30	2011-03-28	Inhibidores no nucleosidicos de la transcriptasa inversa.

Country Status (44)

Country	Link
US (2)	US8486975B2 (2)
EP (2)	EP2552902B1 (2)
JP (2)	JP5281718B2 (2)
KR (1)	KR101421861B1 (2)
CN (1)	CN102971308B (2)
AR (1)	AR080859A1 (2)
AU (1)	AU2011235568B2 (2)
BR (1)	BR112012024691B1 (2)
CA (1)	CA2794377C (2)
CL (1)	CL2012002744A1 (2)
CO (1)	CO6630126A2 (2)
CR (1)	CR20120503A (2)
CY (3)	CY1118774T1 (2)
DK (2)	DK2552902T3 (2)
DO (1)	DOP2012000256A (2)
EA (1)	EA024804B1 (2)
EC (1)	ECSP12012201A (2)
ES (2)	ES2609636T3 (2)
FI (1)	FIC20190021I1 (2)
GE (1)	GEP20156368B (2)
HN (1)	HN2012002039A (2)
HR (2)	HRP20150427T1 (2)
HU (4)	HUE025336T2 (2)
IL (2)	IL222030A (2)
LT (3)	LT2924034T (2)
LU (2)	LUC00113I9 (2)
MA (1)	MA34170B1 (2)
ME (2)	ME02181B (2)
MX (1)	MX2012011379A (2)
MY (1)	MY163979A (2)
NI (1)	NI201200146A (2)
NL (1)	NL300980I2 (2)
NO (2)	NO2019019I1 (2)
NZ (1)	NZ602670A (2)
PE (1)	PE20130158A1 (2)
PH (1)	PH12012501923A1 (2)
PL (2)	PL2552902T3 (2)
PT (2)	PT2552902E (2)
RS (2)	RS54017B1 (2)
SG (1)	SG184347A1 (2)
SI (2)	SI2924034T1 (2)
TN (1)	TN2012000455A1 (2)
TW (1)	TWI458719B (2)
WO (1)	WO2011120133A1 (2)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2924034T1 (sl) *	2010-03-30	2017-05-31	Merck Canada Inc.	Farmacevtski sestavek, ki obsega nenukleozidni inhibitor reverzne transkriptaze
US20140031250A1 (en)	2010-10-07	2014-01-30	David Tsai Ting	Biomarkers of Cancer
CA2882947A1 (en)	2012-09-26	2014-04-03	Merck Sharp & Dohme Corp.	Crystalline form of a reverse transcriptase inhibitor
JO3470B1 (ar)	2012-10-08	2020-07-05	Merck Sharp & Dohme	مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
BR112015012843B8 (pt)	2012-12-05	2023-04-25	Merck Sharp & Dohme	Método para sintetizar o composto
US20160287568A1 (en) *	2013-11-22	2016-10-06	Merck Sharp & Dohme Corp.	Composition of a non-nucleoside reverse transcriptase inhibitor
CA2930585A1 (en) *	2013-12-04	2015-06-11	Merck Sharp & Dohme Corp.	Process for making reverse transcriptase inhibitors
WO2015153304A1 (en)	2014-04-01	2015-10-08	Merck Sharp & Dohme Corp.	Prodrugs of hiv reverse transcriptase inhibitors
US10301624B2 (en)	2014-06-25	2019-05-28	The General Hospital Corporation	Targeting human satellite II (HSATII)
WO2017095761A1 (en)	2015-12-02	2017-06-08	Merck Sharp & Dohme Corp.	Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
US11077050B2 (en)	2017-03-24	2021-08-03	Merck Sharp & Dohme Corp.	Formulation for parenteral administration
RU2019136678A (ru)	2017-04-18	2021-05-18	Сипла Лимитед	Комбинированная терапия для применения в лечении ретровирусных инфекций
JP2021512956A (ja)	2018-02-06	2021-05-20	ザジェネラルホスピタルコーポレイション	腫瘍免疫応答のバイオマーカーとしてのリピートｒｎａ
EP3823632B1 (en) *	2018-07-17	2025-10-29	Merck Sharp & Dohme LLC	Efda in combination with doravirine for use in treating f227c mutated hiv infections
CA3122571C (en)	2018-12-18	2023-08-01	Merck Sharp & Dohme Corp.	Pyrimidone derivatives as selective cytotoxic agents against hiv infected cells
CN110801455B (zh) *	2019-11-12	2020-06-02	河北医科大学第二医院	用于治疗mrsa的药物组合物及其应用
CN114163309B (zh) *	2021-12-27	2023-04-25	甘肃皓天医药科技有限责任公司	一种多拉韦林中间体的制备方法
CN114349690B (zh) *	2022-02-15	2023-04-25	甘肃皓天医药科技有限责任公司	一种多拉韦林中间体合成方法
CN116903590A (zh) *	2023-06-06	2023-10-20	延边大学	一种含杂环结构的吡啶酮类化合物及其制备方法和用途
CN120157613A (zh) *	2023-12-15	2025-06-17	山东诚创蓝海医药科技有限公司	多拉韦林中间体及其应用和合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9904045D0 (sv)	1999-11-09	1999-11-09	Astra Ab	Compounds
TW200423930A (en) *	2003-02-18	2004-11-16	Hoffmann La Roche	Non-nucleoside reverse transcriptase inhibitors
BRPI0408704A (pt)	2003-03-24	2006-03-07	Hoffmann La Roche	benzil-piridazinonas como inibidores de transcriptase reversa
TW200505441A (en)	2003-03-24	2005-02-16	Hoffmann La Roche	Non-nucleoside reverse transcriptase inhibitorsⅠ
US7166738B2 (en)	2004-04-23	2007-01-23	Roche Palo Alto Llc	Non-nucleoside reverse transcriptase inhibitors
DE602005017604D1 (de)	2004-04-23	2009-12-24	Hoffmann La Roche	Inhibitoren der nicht-nukleosid-inhibitoren der reversen transkriptase
CA2592092A1 (en)	2004-12-22	2006-06-29	Pfizer Limited	Nonnucleoside inhibitors of hiv-1 reverse transcriptase
AR057455A1 (es)	2005-07-22	2007-12-05	Merck & Co Inc	Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
WO2007045573A1 (en)	2005-10-19	2007-04-26	F. Hoffmann-La Roche Ag	Phenyl-acetamide nnrt inhibitors
AU2006303367A1 (en)	2005-10-19	2007-04-26	F. Hoffmann-La Roche Ag	N-phenyl phenylacetamide non-nucleoside reverse transcriptase inihibitors
TW200831085A (en)	2006-12-13	2008-08-01	Merck & Co Inc	Non-nucleoside reverse transcriptase inhibitors
CN101952274A (zh)	2007-11-20	2011-01-19	默沙东公司	非核苷逆转录酶抑制剂
SI2924034T1 (sl) *	2010-03-30	2017-05-31	Merck Canada Inc.	Farmacevtski sestavek, ki obsega nenukleozidni inhibitor reverzne transkriptaze

2011
- 2011-03-28 SI SI201131054A patent/SI2924034T1/sl unknown
- 2011-03-28 MX MX2012011379A patent/MX2012011379A/es active IP Right Grant
- 2011-03-28 BR BR112012024691-7A patent/BR112012024691B1/pt active IP Right Grant
- 2011-03-28 PH PH1/2012/501923A patent/PH12012501923A1/en unknown
- 2011-03-28 LT LTEP15157348.2T patent/LT2924034T/lt unknown
- 2011-03-28 EP EP11761856.1A patent/EP2552902B1/en active Active
- 2011-03-28 PT PT117618561T patent/PT2552902E/pt unknown
- 2011-03-28 CN CN201180018074.2A patent/CN102971308B/zh active Active
- 2011-03-28 WO PCT/CA2011/000320 patent/WO2011120133A1/en not_active Ceased
- 2011-03-28 HU HUE11761856A patent/HUE025336T2/en unknown
- 2011-03-28 PL PL11761856T patent/PL2552902T3/pl unknown
- 2011-03-28 PL PL15157348T patent/PL2924034T3/pl unknown
- 2011-03-28 DK DK11761856.1T patent/DK2552902T3/en active
- 2011-03-28 PE PE2012001823A patent/PE20130158A1/es active IP Right Grant
- 2011-03-28 ME MEP-2015-76A patent/ME02181B/me unknown
- 2011-03-28 RS RS20150340A patent/RS54017B1/sr unknown
- 2011-03-28 SI SI201130491T patent/SI2552902T1/sl unknown
- 2011-03-28 EA EA201290976A patent/EA024804B1/ru active Protection Beyond IP Right Term
- 2011-03-28 ES ES15157348.2T patent/ES2609636T3/es active Active
- 2011-03-28 MY MYPI2012004342A patent/MY163979A/en unknown
- 2011-03-28 GE GEAP201112882A patent/GEP20156368B/en unknown
- 2011-03-28 DK DK15157348.2T patent/DK2924034T3/en active
- 2011-03-28 ME MEP-2016-282A patent/ME02570B/me unknown
- 2011-03-28 KR KR1020127025733A patent/KR101421861B1/ko active Active
- 2011-03-28 NZ NZ602670A patent/NZ602670A/en unknown
- 2011-03-28 EP EP15157348.2A patent/EP2924034B1/en active Active
- 2011-03-28 HU HUE15157348A patent/HUE031785T2/en unknown
- 2011-03-28 SG SG2012072401A patent/SG184347A1/en unknown
- 2011-03-28 CA CA2794377A patent/CA2794377C/en active Active
- 2011-03-28 PT PT151573482T patent/PT2924034T/pt unknown
- 2011-03-28 ES ES11761856.1T patent/ES2536295T3/es active Active
- 2011-03-28 RS RS20161093A patent/RS55505B1/sr unknown
- 2011-03-28 MA MA35324A patent/MA34170B1/fr unknown
- 2011-03-28 AU AU2011235568A patent/AU2011235568B2/en active Active
- 2011-03-28 US US13/073,631 patent/US8486975B2/en active Active
- 2011-03-28 JP JP2012538161A patent/JP5281718B2/ja active Active
- 2011-03-28 HR HRP20150427TT patent/HRP20150427T1/hr unknown
- 2011-03-29 AR ARP110101028A patent/AR080859A1/es active IP Right Grant
- 2011-03-29 TW TW100110833A patent/TWI458719B/zh active
2012
- 2012-09-20 IL IL222030A patent/IL222030A/en active Protection Beyond IP Right Term
- 2012-09-20 TN TNP2012000455A patent/TN2012000455A1/en unknown
- 2012-09-27 HN HN2012002039A patent/HN2012002039A/es unknown
- 2012-09-28 DO DO2012000256A patent/DOP2012000256A/es unknown
- 2012-09-28 NI NI201200146A patent/NI201200146A/es unknown
- 2012-09-28 CL CL2012002744A patent/CL2012002744A1/es unknown
- 2012-10-01 CO CO12171897A patent/CO6630126A2/es active IP Right Grant
- 2012-10-01 EC ECSP12012201 patent/ECSP12012201A/es unknown
- 2012-10-01 CR CR20120503A patent/CR20120503A/es unknown
2013
- 2013-05-23 JP JP2013108533A patent/JP5886790B2/ja not_active Expired - Fee Related
- 2013-07-03 US US13/934,633 patent/US20130296382A1/en not_active Abandoned
2014
- 2014-06-23 IL IL233334A patent/IL233334A/en active IP Right Grant
2016
- 2016-12-09 HR HRP20161680TT patent/HRP20161680T1/hr unknown
2017
- 2017-01-25 CY CY20171100114T patent/CY1118774T1/el unknown
2019
- 2019-04-09 HU HUS1900022C patent/HUS1900022I1/hu unknown
- 2019-04-09 HU HUS1900021C patent/HUS1900021I1/hu unknown
- 2019-04-11 LT LTPA2019507C patent/LTC2924034I2/lt unknown
- 2019-04-11 LT LTPA2019506 patent/LTC2552902I2/lt unknown
- 2019-04-16 NL NL300980C patent/NL300980I2/nl unknown
- 2019-04-17 FI FIC20190021C patent/FIC20190021I1/fi unknown
- 2019-04-17 LU LU00113C patent/LUC00113I9/fr unknown
- 2019-04-17 LU LU00114C patent/LUC00114I2/fr unknown
- 2019-04-24 NO NO2019019C patent/NO2019019I1/no unknown
- 2019-04-24 NO NO2019018C patent/NO2019018I1/no unknown
- 2019-05-16 CY CY2019026C patent/CY2019026I1/el unknown
- 2019-05-16 CY CY2019025C patent/CY2019025I1/el unknown

Also Published As

Publication number	Publication date
DK2924034T3 (en)	2017-02-06
CA2794377A1 (en)	2011-10-06
WO2011120133A1 (en)	2011-10-06
EP2552902B1 (en)	2015-03-11
SI2552902T1 (sl)	2015-10-30
HUS1900021I1 (hu)	2019-05-28
NL300980I1 (nl)	2019-04-24
EA024804B1 (ru)	2016-10-31
KR20120128703A (ko)	2012-11-27
GEP20156368B (en)	2015-09-25
AR080859A1 (es)	2012-05-16
PT2924034T (pt)	2017-01-06
DK2552902T3 (en)	2015-06-15
NZ602670A (en)	2014-09-26
CL2012002744A1 (es)	2012-12-14
CA2794377C (en)	2015-06-16
EP2552902A1 (en)	2013-02-06
PH12012501923A1 (en)	2013-02-04
US20130296382A1 (en)	2013-11-07
HK1209121A1 (en)	2016-03-24
HN2012002039A (es)	2015-08-24
US20110245296A1 (en)	2011-10-06
CY2019026I2 (el)	2020-05-29
HUE031785T2 (en)	2017-08-28
EP2924034A1 (en)	2015-09-30
IL233334A (en)	2015-09-24
HUS1900022I1 (hu)	2019-05-28
EA201290976A1 (ru)	2013-03-29
NL300980I2 (nl)	2021-06-17
NO2019019I1 (no)	2019-04-24
PE20130158A1 (es)	2013-02-28
KR101421861B1 (ko)	2014-07-22
CO6630126A2 (es)	2013-03-01
CN102971308B (zh)	2015-02-04
DOP2012000256A (es)	2012-12-15
CN102971308A (zh)	2013-03-13
CY2019025I2 (el)	2019-11-27
PL2552902T3 (pl)	2015-10-30
HRP20150427T1 (hr)	2015-07-03
RS55505B1 (sr)	2017-05-31
LTC2924034I2 (lt)	2020-10-12
BR112012024691B1 (pt)	2020-11-17
LT2924034T (lt)	2016-12-27
RS54017B1 (sr)	2015-10-30
EP2552902A4 (en)	2013-09-04
LUC00113I9 (2)	2024-06-07
JP5281718B2 (ja)	2013-09-04
CY2019025I1 (el)	2019-11-27
TW201139409A (en)	2011-11-16
ECSP12012201A (es)	2012-10-30
AU2011235568A1 (en)	2012-11-01
PT2552902E (pt)	2015-06-02
LUC00114I2 (2)	2020-07-10
HRP20161680T1 (hr)	2017-01-27
IL233334A0 (en)	2014-09-01
SG184347A1 (en)	2012-11-29
AU2011235568B2 (en)	2013-09-12
SI2924034T1 (sl)	2017-05-31
PL2924034T3 (pl)	2017-07-31
JP5886790B2 (ja)	2016-03-16
ES2536295T3 (es)	2015-05-22
ME02570B (me)	2017-06-20
LTPA2019506I1 (lt)	2019-04-25
HUE025336T2 (en)	2016-03-29
BR112012024691A2 (pt)	2019-07-02
HK1175471A1 (en)	2013-07-05
LUC00113I2 (2)	2024-05-22
IL222030A (en)	2014-07-31
JP2013209405A (ja)	2013-10-10
CR20120503A (es)	2013-01-09
NO2019018I1 (no)	2019-04-24
LUC00114I1 (2)	2019-04-17
EP2924034B1 (en)	2016-11-02
MY163979A (en)	2017-11-15
NI201200146A (es)	2013-03-18
FIC20190021I1 (fi)	2019-04-17
LTC2552902I2 (lt)	2019-12-10
ME02181B (me)	2015-10-20
TWI458719B (zh)	2014-11-01
TN2012000455A1 (en)	2014-01-30
LTPA2019507I1 (lt)	2019-04-25
CY1118774T1 (el)	2017-07-12
JP2013510800A (ja)	2013-03-28
MA34170B1 (fr)	2013-04-03
CY2019026I1 (el)	2020-05-29
ES2609636T3 (es)	2017-04-21
US8486975B2 (en)	2013-07-16

Legal Events

Date	Code	Title	Description
2014-01-23	FG	Grant or registration

Publication	Publication Date	Title
DK2552902T3 (en)	2015-06-15	Non-nucleoside reverse transcriptase inhibitors
HUP0500163A2 (hu)	2005-05-30	Pirazolo [5,1-b] kinazolin származékok és ezeket tartalmazó gyógyszerkészítmények mint az IMPDH enzim inhibitorai
AU2015241247B2 (en)	2017-09-14	Prodrugs of HIV reverse transcriptase inhibitors
JP2008546839A (ja)	2008-12-25	非ヌクレオシド逆転写酵素阻害剤
HK1209121B (en)	2017-08-18	Pharmaceutical composition comprising a non-nucleoside reverse transcriptase inhibitor
JP2009504652A (ja)	2009-02-05	非ヌクレオシド逆転写酵素阻害剤
HK1175471B (en)	2015-08-21	Non-nucleoside reverse transcriptase inhibitors
HK40042531A (en)	2021-09-03	Prodrugs of hiv reverse transcriptase inhibitors